Hydroxychloroquine Unlikely To Benefit Covid-19 Patients: Study

Anti-malaria drug Hydroxychloroquine may not benefit hospitalized patients with coronavirus (COVID-19), according to clinical trial conducted by the National Institutes of Health (NIH). The NIH stopped the clinical trial after its data and safety monitoring board (DSMB) determined that while there was no harm, Hydroxychloroquine provides no benefit.